One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit
247Wallst·2026-01-15 19:47

文章核心观点 - 两家专注于罕见病领域的生物技术公司Corcept Therapeutics和Amicus Therapeutics公布了2025年第三季度业绩，它们分别处于盈利状况的两个极端 [1] 公司业绩对比 - Corcept Therapeutics和Amicus Therapeutics均为罕见病生物技术公司 [1] - 两家公司2025年第三季度的业绩结果凸显了它们在盈利能力谱系上的两端位置 [1]

cept Therapeutics rporated-One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit - Reportify